AGP Picks
View all

The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on November 9, 2026

Neutrolis Doses First Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Phase 1b LIBERATE-I Trial of NTR-1011 and Will Present Phase 1a Data at ACR Convergence 2026
Tectonic Therapeutic to Participate in Upcoming Investor Conferences
Mycroft Mind and MicroEJ Bring Energy Analytics Directly into Smart Meters
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
Marengo Presents Interim Phase 2 STARt-002 Results for First-in-Class Selective T-Cell Agonist Invikafusp Alfa Plus Sacituzumab Govitecan Across Two Metastatic Breast Cancer Cohorts in Oral Presentation at SITC 2026
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results 
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Akamai Announces Proposed Offering of Convertible Senior Notes
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Boston Examiner

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.